PHIO — Phio Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Phio Pharmaceuticals Corp reports results for the quarter ended in December - Earnings Summary
Brief: Phio Pharmaceuticals Posts FY Loss Of $10.10 Per Share
Phio Pharmaceuticals Corp expected to post a loss of $3.24 a share - Earnings Preview
Brief: Phio Pharmaceuticals Names Robert Bitterman As Chief Executive Officer
Brief: Phio Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements
U.S. STOCKS ON THE MOVE-Ralph Lauren, J.M. Smucker, Lions Gate
U.S. STOCKS ON THE MOVE-Silvergate Capital, PayPal, Spotify
U.S. STOCKS ON THE MOVE-Cloudflare, Coursera, Corsair Gaming
Brief: Phio Pharmaceuticals Announces Positive DMC Recommendation
Phio Pharma up on positive review for skin cancer therapy trial
Brief: Phio Pharmaceuticals Announces Reverse Stock Split
Brief: Phio Pharmaceuticals Announces Regulatory Clearance Of Clinical Trial With Ph-762 And Agonox's Tumor Infiltrating Lymphocytes (Agx148) To Treat Solid Tumors
Brief: Phio Pharmaceuticals Announces New Clinical Program To Study Ph-762 For The Treatment Of Cutaneous Squamous Cell Carcinoma
Phio Pharmaceuticals Corp reports results for the quarter ended in September - Earnings Summary
Brief: Phio Announces New Appointments To Leadership Team, Reports On Third Quarter 2022 Financial Results And Provides Business Update
Phio Pharmaceuticals Corp expected to post earnings of 36cents a share - Earnings Preview
Brief: Phio Pharmaceuticals Corp - Announces Appointment Of Robert Bitterman As Executive Chairman
Brief: Phio Pharmaceuticals Announces Preclinical Data Demonstrating PH-762 Enhances Persistence Of T Cells For Tumor Cell Killing
Phio Pharmaceuticals Corp reports results for the quarter ended in June - Earnings Summary